ATE309817T1 - Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs - Google Patents

Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs

Info

Publication number
ATE309817T1
ATE309817T1 AT01956705T AT01956705T ATE309817T1 AT E309817 T1 ATE309817 T1 AT E309817T1 AT 01956705 T AT01956705 T AT 01956705T AT 01956705 T AT01956705 T AT 01956705T AT E309817 T1 ATE309817 T1 AT E309817T1
Authority
AT
Austria
Prior art keywords
treatment
cancer
trkaig2
prevention
pharmaceutical composition
Prior art date
Application number
AT01956705T
Other languages
English (en)
Inventor
Shelley Jane Allen
David Dawbarn
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol filed Critical Univ Bristol
Application granted granted Critical
Publication of ATE309817T1 publication Critical patent/ATE309817T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01956705T 2000-08-18 2001-08-17 Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs ATE309817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020504.7A GB0020504D0 (en) 2000-08-18 2000-08-18 Therapeutic method
PCT/GB2001/003682 WO2002015924A1 (en) 2000-08-18 2001-08-17 Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer

Publications (1)

Publication Number Publication Date
ATE309817T1 true ATE309817T1 (de) 2005-12-15

Family

ID=9897960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01956705T ATE309817T1 (de) 2000-08-18 2001-08-17 Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs

Country Status (10)

Country Link
US (2) US20040037831A1 (de)
EP (1) EP1309338B1 (de)
JP (1) JP2004506694A (de)
KR (1) KR20030040405A (de)
AT (1) ATE309817T1 (de)
AU (2) AU2001278624B2 (de)
CA (1) CA2420051A1 (de)
DE (1) DE60115054T2 (de)
GB (1) GB0020504D0 (de)
WO (1) WO2002015924A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096753A1 (en) * 1998-04-09 2003-05-22 Robertson Alan George Simpson Therapeutic agent
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
GB0020504D0 (en) * 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
GB0122400D0 (en) * 2001-09-17 2001-11-07 Univ Bristol Polypeptide purification method
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
BRPI0407375A (pt) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
EP3372614B1 (de) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonististen
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
EP1857146A1 (de) * 2006-05-16 2007-11-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Respiratonsstörungen
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK166763C (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5789187A (en) * 1992-08-27 1998-08-04 Worcester Foundation For Experimental Biology Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6136581A (en) * 1996-11-22 2000-10-24 Sugen, Inc. Kinase genes and uses
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
US20030096753A1 (en) * 1998-04-09 2003-05-22 Robertson Alan George Simpson Therapeutic agent
GB0020504D0 (en) * 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
GB0122400D0 (en) * 2001-09-17 2001-11-07 Univ Bristol Polypeptide purification method

Also Published As

Publication number Publication date
AU7862401A (en) 2002-03-04
US20040037831A1 (en) 2004-02-26
DE60115054T2 (de) 2006-07-27
AU2001278624B2 (en) 2007-01-18
CA2420051A1 (en) 2002-02-28
EP1309338B1 (de) 2005-11-16
GB0020504D0 (en) 2000-10-11
EP1309338A1 (de) 2003-05-14
JP2004506694A (ja) 2004-03-04
KR20030040405A (ko) 2003-05-22
US20070105773A1 (en) 2007-05-10
WO2002015924A1 (en) 2002-02-28
DE60115054D1 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
PL368686A1 (en) Novel aminobenzoephenones
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
DE10292147D2 (de) Physiologisch verträgliche Kalium-und Magnesiumsalze enthaltendes pharmazeutisches Präparat sowie dessen Verwendung zur Prophylaxe und/oder Therapie von QT-Zeitverlängerungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1309338

Country of ref document: EP

REN Ceased due to non-payment of the annual fee